News | December 13, 2006

Possis Secures Piece of IVC Treatment Pie

Possis Medical, Inc. has closed a $2.5 million equity investment in Rafael Medical Technologies, Inc., which gives Possis 15 percent ownership in Rafael Medical and a three-year option to purchase the company.

The deal does hand Possis an obligation to provide up to $1.5 million of secured debt financing but also offers Possis one seat on Rafael's board of directors. Rafael Medical is developing its proprietary SafeFlo inferior vena cava (IVC) filter. It is estimated that by 2010, the U.S. market for IVC filters will total nearly $200 million. Rafael Medical is conducting a clinical trial of the SafeFlo filter at multiple sites in the U.S. and Europe; a 510(k) submission to the FDA is expected within 12 to 18 months.

The IVC is the large vein that carries de-oxygenated blood from the lower body back to the heart and then to the lungs for re-oxygenation. In certain individuals, the formation of blood clots in the deep veins of the legs, a condition known as deep vein thrombosis (DVT), can lead to the migration of blood clots to the lungs causing a pulmonary embolism (PE), an often fatal condition. The U.S. patented SafeFlo IVC filter is a minimally invasive and retrievable filter designed to prevent the migration of thrombus to the lungs and the potentially devastating effects of PE.

The purchase option may be exercised by Possis at any time, at the discretion of Possis, prior to the earlier of 60 days after Rafael receives U.S. FDA marketing clearance, or November 29, 2009. If Possis determines to exercise the option, it will pay Rafael Medical shareholders an initial purchase price of $12 million in cash, less any debt outstanding, and will be obligated to make earn-out payments based on a multiple of revenue generated from the SafeFlo IVC filter during the three years commencing six months after closing of the transaction. Total payments, including the $2.5 million initial equity investment, will not exceed $54 million.

Related Content

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
News | January 21, 2015
The number of IVC filters placed has more than doubled in the last 10 years, and by some estimates, less than half of...
Vena Cava Filters, Embolic protection, Pulmonary Embolism, Venous Therapies

Image courtesy of Society of Vascular Surgery

Feature | January 05, 2015
The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (...
News | August 06, 2014
Decision Resources Group finds that the United States clot management device market will expand through 2022,...
Cook Medical SCAI CIVIC PRESERVE Clincal Studies Vena Cava Filter
News | June 05, 2014
Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of...
Argon Medical OptionElite retrievable inferior vena cava (IVC) filter guidewire
Technology | January 23, 2014
Argon Medical Devices Inc. received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing the...
Angiotech Vena Cava Filter
News | April 18, 2013
One venous puncture, rather than two, is a safe and effective approach to intravascular ultrasound-guided inferior vena...
News | April 05, 2013
Continuing its commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (...
Sponsored Content | Videos | Vena Cava Filters| July 24, 2012
This video, provided by Crux Biomedical, demonstrates the implantation of the FDA-cleared Crux VCF inferior vena cava
Technology | July 20, 2012
July 20, 2012 — Crux Biomedical announced it has received U.S. Food and Drug Administration (FDA) clearance for its...
Overlay Init